Loading stock data…
STXS
$1.93+0.06 (+3.21%)
Market ClosedLast close May 1
Stereotaxis, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Stereotaxis, Inc. in the Healthcare sector is trading at $1.93. The stock is currently near its 52-week low of $1.74, remaining 20.9% below its 200-day moving average. Technical signals show neutral RSI of 51 and bearish MACD signal, explaining why STXS maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.93
Potential Upside
5%
Whystock Fair Value$2.03
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$191.06M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.42
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-115.61%
Volume
Today's trading volume
333,722
Recent News
Why Stereotaxis (STXS) Could Be One of the Best Robotics Stocks to Buy Under $30
With a street-high upside potential of 159.0%, Stereotaxis, Inc. (NYSE:STXS) ranks among the 10 best robotics stocks to buy under $30. The first time the company’s MAGiC catheter was used in the U.S., it did not ease into things gently. On April 22, 2026, Stereotaxis, Inc. (NYSE:STXS) saw its newly FDA-approved robotic magnetic ablation catheter […]
Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval
STXS stock gains after first U.S. MAGiC procedures, marking a key milestone in robotic cardiac care and boosting its growth outlook.
STXS to Acquire Robocath to Lead in Endovascular Robotics Market
Stereotaxis expands in robotic surgery with Robocath acquisition, aiming to build a comprehensive endovascular platform and unlock growth opportunities.
Stereotaxis to acquire Robocath for up to $45m
The acquisition is intended to strengthen Stereotaxis’ position in the sector by expanding its platform.
Stereotaxis to buy Robocath for up to $45M
The deal combines Stereotaxis’ magnetic navigation technology and Robocath’s mechanical robotic system, strengthening the company’s position in endovascular surgery, said CEO David Fischel.